Skip to Main Content

Author Details

Alan Melcher
The Institute of Cancer Research
1994
223
59
PMIDPaper TitleJournal TitlePublished Year
36517200Corrigendum to "Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers": Translational Oncology 2022 Nov; 25:101511.Transl Oncol2023
37841530Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment.Mol Ther Oncolytics2023
37675296Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?Ann Transl Med2023
37077714Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.Mol Ther Oncolytics2023
37363104Updates on radiotherapy-immunotherapy combinations: Proceedings of 6<sup>th</sup> annual ImmunoRad conference.Oncoimmunology2023
35338089CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.J Immunother Cancer2022
35439304Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.Cancer Immunol Res2022
35821679Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors.Neurooncol Adv2022
35393414Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy.Nat Commun2022
35565310Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.Cancers (Basel)2022
35417192Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.Sci Transl Med2022
35558159OX40 and 4-1BB delineate distinct immune profiles in sarcoma.Oncoimmunology2022
36106115Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.Front Oncol2022
35964339Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers.Transl Oncol2022
36238579PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation.Clin Transl Radiat Oncol2022
36161312Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.Clin Cancer Res2022
35156714Oncolytic virus treatment differentially affects the CD56<sup>dim</sup> and CD56<sup>bright</sup> NK cell subsets in vivo and regulates a spectrum of human NK cell activity.Immunology2022
35314434Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.J Immunother Cancer2022
34998656RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.Clin Oncol (R Coll Radiol)2022
32324860Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.J Natl Cancer Inst2021
33854970Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma.Front Oncol2021
33741729Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.J Immunother Cancer2021
33678606Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.J Immunother Cancer2021
33707311Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model.J Immunother Cancer2021
33558423APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.Clin Cancer Res2021
33772027Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.Nat Commun2021
34882456Oncolytic virotherapy as immunotherapy.Science2021
34733287Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.Front Immunol2021
34301814Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.J Immunother Cancer2021
34103355On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.J Immunother Cancer2021
34359755Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.Cancers (Basel)2021
34359574Oncolytic Virus Immunotherapy.Cancers (Basel)2021
32883872Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.Gut2021
32128359The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.Mol Ther Oncolytics2020
33665363Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.Mol Ther Oncolytics2020
31784984Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.Clin Exp Immunol2020
32067509Combination therapy with oncolytic viruses and immune checkpoint inhibitors.Expert Opin Biol Ther2020
32034147APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.Nat Commun2020
33133066The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An <i>In Silico</i> Study.Front Immunol2020
33293514A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients.Cell Death Discov2020
32759235Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.J Immunother Cancer2020
32555433Author Correction: STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy.Nat Cell Biol2020
32419365RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.EMBO Mol Med2020
32248073Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy.Eur J Cancer2020
32209603Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.J Immunother Cancer2020
32513517Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer.Clin Oncol (R Coll Radiol)2020
32483388STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy.Nat Cell Biol2020
32161398Inflammatory microenvironment remodelling by tumour cells after radiotherapy.Nat Rev Cancer2020
30632153The immunological consequences of radiation-induced DNA damage.J Pathol2019
31273010Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.Clin Cancer Res2019
  • 1 - 50 of 223

Recommended Authors

Laurel B Darragh
University of Colorado Denver at Anschutz Medical Campus
Career Start Year 2018
Number of shared co-authors 2
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Tori N Yamamoto
National Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
Aleksandra A Pandyra
Hematology and Clinical Immunology, Heinrich-Heine University Dusseldorf
Career Start Year 2003
Number of shared co-authors 1
Gavin P Dunn
Washington University School of Medicine
Career Start Year 2002
Number of shared co-authors 0
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Career Start Year 2002
Number of shared co-authors 2
Marta M Alonso
CIMA-Universidad de Navarra
Career Start Year 2001
Number of shared co-authors 2
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year 1999
Number of shared co-authors 1
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Masaki Terabe
National Cancer Institute
Career Start Year 1997
Number of shared co-authors 0
Sunil J Advani
Moores Cancer Center, University of California San Diego
Career Start Year 1997
Number of shared co-authors 0
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 2
Sacha Gnjatic
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 5
Zhiya Yu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 0
Tim F Greten
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1994
Number of shared co-authors 1
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 3
Lawrence Fong
University of California san francisco
Career Start Year 1993
Number of shared co-authors 1
Firouzeh Korangy
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1992
Number of shared co-authors 1
Veena Kapoor
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 2
Craig L Slingluff
University of Virginia
Career Start Year 1987
Number of shared co-authors 1
Juan Fueyo
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 4
Mary L Disis
University of Washington Medicine Cancer Vaccine Institute, University of Washington
Career Start Year 1986
Number of shared co-authors 2
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Career Start Year 1985
Number of shared co-authors 1
Nicholas P Restifo
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 1985
Number of shared co-authors 0
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 0
John T Schiller
David Geffen School of Medicine at university of california los angeles
Career Start Year 1984
Number of shared co-authors 1
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Career Start Year 1972
Number of shared co-authors 5
George Yancey Gillespie
Heersink School of Medicine, The University of Alabama at Birmingham
Career Start Year 1970
Number of shared co-authors 0
Steven A Rosenberg
University of Colorado School of Medicine
Career Start Year 1961
Number of shared co-authors 1

Collaborators

Peter J Selby
College of Agriculture and Life Sciences, Cornell University
Co-authored papers 56
David Mansfield
Institute of Cancer Research
Co-authored papers 20
Victoria A Jennings
Leeds Institute of Medical Research at St James's, University of Leeds
Co-authored papers 15
Michael J Gough
Earle A. Chiles Research Institute, Providence Cancer Institute
Co-authored papers 10
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 9
John C Bell
Ottawa Hospital Research Institute
Co-authored papers 5
Gemma Migneco
Leeds Institute of Medical Research at St James's, University of Leeds
Co-authored papers 5
Rebecca C Auer
The Ottawa Hospital Research Institute
Co-authored papers 3
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Co-authored papers 3
Reuben S Harris
University of Texas Health San Antonio
Co-authored papers 3
Sandra Demaria
Weill Cornell Medical College
Co-authored papers 3
Syed Haider
Institute of Cancer Research
Co-authored papers 3
Richard J Bram
Mayo Clinic College of Medicine
Co-authored papers 2
Almohanad A Alkayyal
College of Applied Medical Sciences, University of Tabuk
Co-authored papers 2
Carolina S Ilkow
Ottawa Hospital Research Institute
Co-authored papers 2
Christiano Tanese de Souza
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 2
Angel M Carcaboso
Co-authored papers 2
Silvia C Formenti
Weill Cornell Medical College
Co-authored papers 2
Brian A Keller
The Ottawa Hospital/University of Ottawa
Co-authored papers 2
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Co-authored papers 1
Sheila Spada
Weill Cornell Medical College
Co-authored papers 1
Giuseppe Pugliese
Ottawa Hospital Research Institute
Co-authored papers 1
Justin H Gundelach
Mayo Clinic
Co-authored papers 1
Bradley Austin
Ottawa Hospital Research Institute
Co-authored papers 1
Laura Santambrogio
Weill Cornell School of Medicine
Co-authored papers 1
Timothy A Chan
Cleveland Clinic.
Co-authored papers 1
Hayley E McKay
Ottawa Hospital Research Institute
Co-authored papers 1
Katey J Rayner
University of Ottawa
Co-authored papers 1
Abera Surendran
Ottawa Hospital Research Institute, The Ottawa Hospital
Co-authored papers 1
Larissa A Pikor
Ottawa Hospital Research Institute
Co-authored papers 1
Release 1.2